Partial Revocation Of EPO Patent On Sofosbuvir, Key For Hepatitis C
Following a public hearing at its headquarters in Munich, the European Patent Office (EPO) decided to reject in part the arguments made by Gilead Sciences to uphold their patent on sofosbuvir, according to a non-profit group.







